Sorrento Develops STI-4398 (COVIDTRAP Protein) to Prevent and Treat COVID-19

 Sorrento Develops STI-4398 (COVIDTRAP Protein) to Prevent and Treat COVID-19

Sorrento Develops STI-4398 (COVIDTRAP Protein) to Prevent and Treat COVID-19

Shots:

  • The company has created a preclinical batch of the STI-4398 (COVIDTRAP) protein to begin testing its neutralization and blocking activity in preventing the SARS-CoV-2 virus from infecting ACE2-expressing cells
  • The in vitro cell studies for SARS-CoVID-2 virus infection and neutralization are anticipated to be conducted in the next few wks. in collaboration with world-leading coronavirus experts. STI-4398 is in the cGMP cell line development stage and could be ready for high yield production in Sorrento’s facilities in San Diego for clinical studies and commercialization following the regulatory approvals   
  • STI-4398 is an ACE2-Fc protein targeting S1 domain of the spike protein of the SARS-CoV-2 virus and preserve the ACE2 enzyme activity in converting angiotensin II to angiotensin 1-7, resulting in reduced vasoconstriction and increased blood flow to the infected lung tissue

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: Sorrento

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post